Clinical trials: Bleeding Diathesis
Joint Bleed, Hemophilia A
Handheld Ultrasound (HHUS) for Home Use in Hemophilia
This is a study in 3 phases that will assess the feasibility and utility of handheld home ultrasound (HHUS) in a patient's home to assess whether a painful episode in the elbow, knee or ankle is a bleed or not.
- Trial name
- HHUS (NCT04131920)
- Testing
- handheld ultrasound: Philips Lumify integrated tele-ultrasound powered by Reacts collaborative platform
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington Institute for Coagulation
Congenital Hemophilia A
Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A
This is an international, multicenter, open-label study to assess the efficacy, safety, and pharmacokinetic (PK) profile of rVIII-SingleChain in pediatric patients with severe hemophilia A.
- Trial name
- NCT02093897
- Testing
- rVIII-SingleChain
- Where
- 37 sites in United States, Australia and 17 more
- Volunteers
- 84 people
- Sponsor
- CSL Behring
Brain Injuries, Traumatic, Coagulopathy
The Influence of Noradrenaline on Coagulation and Fibrinolysis in Severe Isolated Brain Injury
Aim of the study The investigators aim to establish: Whether noradrenaline (NA) infusion has a significant effect on coagulation and fibrinolysis in patients with severe traumatic brain injury (TBI).
- Conditions
- Brain Injuries, Traumatic, Coagulopathy, Coagulation Defect; Acquired, Coagulation Defect; Bleeding
- Trial name
- NCT04515420
- Testing
- noradrenaline
- Volunteers
- 60 people
- Sponsor
- University Medical Centre Ljubljana
ITP - Immune Thrombocytopenia
Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study
This is a single-center, open label pilot trial where patients with primary ITP who require second line treatment will be offered avatrombopag at a reduced starting dose, adjusted thereafter according to the response and…
- Trial name
- Ava dosing (NCT07133659)
- Testing
- Avatrombopag 20 mg Oral Tablet
- Where
- Iraq
- Volunteers
- 25 people
- Sponsor
- Al-Mustansiriyah University
Perioperative Hemorrhage, Dilutional Coagulopathy
Impact of Balanced Crystalloid and Colloid Infusion on Haemostasis in Healthy Male Volunteers
The project focuses on perioperative bleeding that requires transfusion of blood products and supplementation of intravascular volume with crystalloids and colloids.
- Trial name
- NCT05148650
- Testing
- Standard laboratory coagulation tests and rotational thromboelastometry measurements
- Where
- Poland
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Medical University of Silesia
ITP - Immune Thrombocytopenia
Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid Failure
This study aims to evaluate the efficacy and safety of Ripertamab in combination with Eltrombopag compared to Eltrombopag alone for patients with Primary Immune Thrombocytopenia (ITP) who have not responded to or have relapsed…
- Trial name
- RPE-ITP (NCT06790888)
- Testing
- Ripertamab/Eltrombopag, Eltrombopag
- Volunteers
- 78 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Idiopathic Thrombocytopenic Purpura
P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
The purpose of this study is to evaluate the efficacy and safety of AMG 531 compared with placebo in thrombocytopenic Japanese subjects with immune (idiopathic) thrombocytopenic purpura (ITP) .
- Trial name
- NCT00603642
- Testing
- AMG 531
- Volunteers
- 34 people
- Sponsor
- Amgen
Hemophilia A
Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast
Assessment of the outcomes of prophylaxis with Emicizumab in children with severe hemophilia A in Ivory Coast
- Trial name
- NCT05279924
- Testing
- Prophylaxis with Emicizumab
- Where
- Côte d’Ivoire
- Volunteers
- 33 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Oncologic Diseases, Coagulation Defect
Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs
Evaluation of the Effect of metamizole (Optalgin®) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)
- Conditions
- Oncologic Diseases, Coagulation Defect, Pain Management
- Trial name
- NCT07384013
- Testing
- metamizole
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Rambam Health Care Campus
Acquired Thrombotic Thrombocytopenic Purpura
Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
This study was a Phase II, single-blind, randomized, placebo-controlled trial to determine whether anti-vWF Nanobody is safe and effective as adjunctive treatment in patients with aTTP.
- Trial name
- TITAN (NCT01151423)
- Testing
- Caplacizumab
- Where
- 51 sites in United States, Australia and 11 more
- Volunteers
- 75 people
- Sponsor
- Ablynx, a Sanofi company
Immune Mediated Anemia, Immune Mediated Thrombocytopenia
Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias
Background: People who have a blood stem cell transplant can sometimes develop cytopenia. This means that their levels of one or more types of blood cell, such as the red cells or platelets, are lower than they should be.
- Conditions
- Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
- Trial name
- NCT05509582
- Testing
- fostamatinib
- Where
- United States
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Von Willebrand Disease, Type 1
Evaluation of Bleeding Score in Egyptian Patients With vWD Type I and Correlate it With Laboratory Parameters
Applying the ISTH-BAT questionnaire on Egyptian patients with type I VWD aiming to correlate the BS with the laboratory findings
- Trial name
- NCT03915873
- Testing
- The von Willebrand Antigen level
- Volunteers
- 20 people
- Sponsor
- Assiut University
Immune Thrombocytopenia
Comparison Between Methyl Prednisolone and Intravenous Dexamethazone in Severe Immune Thrombocytopenic Purpra
Immune thrombocytopenic purpra(ITP) is an autoimmune thrombocytopenic syndrome characterized by decreased platelet count and increased risk of bleeding, primarily due to immunoglobulins G(IgG)autoantibodies opsonizing the…
- Trial name
- NCT03183284
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Hemophilia
Bleeding Symptoms of Carriers of Hemophilia A and B
To collect and analyze data on female carriers of severe and moderate hemophilia A and B.
- Trial name
- NCT01029808
- Where
- Sweden
- Volunteers
- 126 people
- Sponsor
- Sahlgrenska University Hospital
Severe Sepsis
4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock
Data on 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene are limited in Asian patients with sepsis. Therefore, the investigators aim to prospectively investigate the incidence of 4G/5G polymorphism and its…
- Trial name
- NCT01211899
- Volunteers
- 160 people
- Sponsor
- Hallym University Medical Center
Hemophilia A
A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors
This is a phase IIIb, single arm, open-label, multi-center study to evaluate the safety and tolerability of emicizumab in participants with congenital hemophilia A who have documented inhibitors against Factor VIII (FVIII) at…
- Trial name
- STASEY (NCT03191799)
- Testing
- Emicizumab
- Where
- 72 sites in Australia, Belgium and 22 more
- Volunteers
- 195 people
- Sponsor
- Hoffmann-La Roche
Congenital Bleeding Disorder, Haemophilia A
Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A
This study is conducted in Europe, and North and South America. The aim of this study is to provide additional documentation of the immunogenicity, and obtain additional clinical data, of turoctocog alfa in the setting of normal…
- Trial name
- guardian™ 5 (NCT02035384)
- Testing
- turoctocog alfa
- Where
- 41 sites in United States, Austria and 13 more
- Volunteers
- 69 people
- Sponsor
- Novo Nordisk A/S
Hemophilia
Imaging of Arthropathy in Boys With Hemophilia in China
Hemophilia is a genetic condition characterized by marked phenotypic heterogeneity. Bleeding into a joint is the single most important risk factor for the development of hemophilic arthropathy (HA).
- Trial name
- NCT03914716
- Testing
- Study group
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Andrea Doria
Haemophilia B
A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France
Alprolix (rFIXFc) is a recombinant extended half-life coagulation factor product. The purpose of this non-interventional study is to describe the real-world usage and effectiveness of Alprolix in the on-demand and prophylactic…
- Trial name
- B-SURE (NCT03655340)
- Testing
- Alprolix
- Where
- 18 sites in France
- Volunteers
- 91 people
- Sponsor
- Swedish Orphan Biovitrum
Hemophilia A and B
Comparison of 30-Second Sit-to-Stand Test Performance Between Individuals With Hemophilia and Healthy Peers
Hemophilia is an inherited bleeding disorder characterized by recurrent musculoskeletal bleeding, particularly into joints, leading to impaired physical function and reduced functional performance.
- Trial name
- NCT07736976
- Where
- Turkey (Türkiye)
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Bahçeşehir University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.